8-K
filed September 20, 2024, 7:59 PM ET
ticker FBRX
CIK 0001419041
leadership
confidence high
sentiment neutral
materiality 0.60
Forte Biosciences appoints Richard Vincent and Shiv Kapoor to board; settles Camac lawsuit for $1.5M
Forte Biosciences, Inc.
- Donald A. Williams and Lawrence Eichenfield resigned from board effective Sept 17, 2024, not due to any disagreement.
- Richard Vincent and Shiv Kapoor appointed as Class II directors; to stand for election at 2025 annual meeting.
- Steven Kornfeld and Scott Brun reclassified from Class II to Class III to maintain class sizes.
- Camac Fund lawsuit settled; company to pay $1.5M for attorneys' fees; case dismissed with prejudice as to Camac; Standstill Agreement stands.
- Board established Strategic Committee of independent directors; Rights Agreement (poison pill) expired July 12, 2024, not renewed.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lawrence Eichenfield resigned as Director at Forte Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard Vincent was appointed as Director at Forte Biosciences, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Donald A. Williams resigned as Director at Forte Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Shiv Kapoor was appointed as Director at Forte Biosciences, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.